Delaware
|
68-0370244
|
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(I.R.S. Employer Identification No.)
|
Large Accelerated Filer
o
|
Accelerated Filer
o
|
Non-Accelerated Filer
o
(Do not check if a smaller reporting company)
|
Smaller reporting company
þ
|
|
|
Page
|
||
|
PART I. FINANCIAL INFORMATION
|
|
||
Item 1.
|
|
|||
|
3
|
|||
|
4
|
|||
|
5
|
|||
|
6
|
|||
Item 2.
|
19
|
|||
Item 3.
|
27
|
|||
Item 4.
|
28
|
|||
|
PART II. OTHER INFORMATION
|
|
||
Item 1.
|
29
|
|||
Item 1A.
|
29
|
|||
Item 2.
|
39
|
|||
Item 3.
|
39
|
|||
Item 4.
|
39
|
|||
Item 5.
|
39
|
|||
Item 6.
|
39
|
|||
Signatures |
39
|
|
September 30,
2013
|
March 31,
2013*
|
|
|||||
ASSETS
|
|
|||||||
Current assets:
|
|
|||||||
Cash and cash equivalents
|
$
|
2,791
|
$
|
4,039
|
||||
Accounts receivable
|
250
|
250
|
||||||
Prepaid expenses and other current assets
|
110
|
102
|
||||||
Other assets of discontinued operations
|
365
|
11
|
||||||
Total current assets
|
3,516
|
4,402
|
||||||
Property and equipment, net
|
138
|
142
|
||||||
Intangible assets, net
|
1,385
|
1,490
|
||||||
Goodwill
|
603
|
603
|
||||||
Investment in convertible promissory note
|
362
|
345
|
||||||
Total assets
|
$
|
6,004
|
$
|
6,982
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable, accrued expenses and other current liabilities
|
$
|
195
|
$
|
167
|
||||
Common stock warrant liability
|
-
|
10
|
||||||
Liabilities of discontinued operations
|
89
|
16
|
||||||
Total current liabilities
|
284
|
193
|
||||||
Deferred tax liability
|
540
|
581
|
||||||
Promissory note
|
507
|
504
|
||||||
Other long term liabilities
|
12
|
--
|
||||||
Total liabilities
|
$
|
1,343
|
$
|
1,278
|
||||
|
||||||||
Stockholders’ equity:
|
||||||||
Preferred stock, $0.01 par value; 5,000,000 shares authorized; none issued and outstanding
|
--
|
--
|
||||||
Common stock, $0.01 par value; 50,000,000 shares authorized; 1,952,960 shares issued and outstanding at September 30, 2013 and March 31, 2013, respectively
|
19
|
19
|
||||||
Additional paid-in capital
|
130,777
|
130,602
|
||||||
Accumulated other comprehensive loss
|
--
|
(142
|
)
|
|||||
Accumulated deficit
|
(126,135
|
)
|
(124,775
|
)
|
||||
Total stockholders’ equity
|
4,661
|
5,704
|
||||||
Total liabilities and stockholders’ equity
|
$
|
6,004
|
$
|
6,982
|
|
Three Months Ended
September 30,
|
Six Months Ended
September 30,
|
||||||||||||||
|
2013
|
2012
|
2013
|
2012
|
||||||||||||
|
|
|
|
|
||||||||||||
Revenue
|
$
|
251
|
$
|
50
|
$
|
521
|
$
|
50
|
||||||||
Revenue - related party
|
--
|
25
|
--
|
50
|
||||||||||||
Total revenue
|
251
|
75
|
521
|
100
|
||||||||||||
Cost of revenue
|
18
|
20
|
36
|
20
|
||||||||||||
Gross profit
|
233
|
55
|
485
|
80
|
||||||||||||
Operating expenses:
|
||||||||||||||||
Engineering
|
457
|
328
|
671
|
328
|
||||||||||||
Research and development
|
27
|
--
|
157
|
--
|
||||||||||||
Sales and marketing
|
63
|
49
|
122
|
49
|
||||||||||||
General and administrative
|
558
|
970
|
1,117
|
1,682
|
||||||||||||
Total operating expenses
|
1,105
|
1,347
|
2,067
|
2,059
|
||||||||||||
Operating loss
|
(872
|
)
|
(1,292
|
)
|
(1,582
|
)
|
(1,979
|
)
|
||||||||
Other income, net
|
16
|
11
|
26
|
20
|
||||||||||||
Loss before income tax benefit
|
(856
|
)
|
(1,281
|
)
|
(1,556
|
)
|
(1,959
|
)
|
||||||||
Income tax benefit
|
(20
|
)
|
-
|
(41
|
)
|
-
|
||||||||||
Loss from continuing operations
|
(836
|
)
|
(1,281
|
)
|
(1,515
|
)
|
(1,959
|
)
|
||||||||
Gain on sale of discontinued operations, net of taxes
|
267
|
-
|
267
|
-
|
||||||||||||
Income (loss) from discontinued operations, net of taxes
|
6
|
(3
|
)
|
(112
|
)
|
(4
|
)
|
|||||||||
Net income (loss) from discontinued operations, net of taxes
|
273
|
(3
|
)
|
155
|
(4
|
)
|
||||||||||
|
||||||||||||||||
Net loss
|
(563
|
)
|
(1,284
|
)
|
(1,360
|
)
|
(1,963
|
)
|
||||||||
|
||||||||||||||||
Foreign currency translation
|
--
|
--
|
--
|
--
|
||||||||||||
Comprehensive loss
|
$
|
(563
|
)
|
$
|
(1,284
|
)
|
$
|
(1,360
|
)
|
$
|
(1,963
|
)
|
||||
|
||||||||||||||||
Net loss per share from continuing operations:
|
||||||||||||||||
Basic and diluted
|
$
|
(0.43
|
)
|
$
|
(0.68
|
)
|
$
|
(0.78
|
)
|
$
|
(1.13
|
)
|
||||
Net income (loss) per share from discontinued operations:
|
||||||||||||||||
Basic and diluted
|
$
|
0.14
|
$
|
-
|
$
|
0.08
|
$
|
-
|
||||||||
Net loss per share:
|
||||||||||||||||
Basic and diluted
|
$
|
(0.29
|
)
|
$
|
(0.68
|
)
|
$
|
(0.70
|
)
|
$
|
(1.13
|
)
|
||||
|
||||||||||||||||
Weighted-average shares used in per share computation:
|
||||||||||||||||
Basic and diluted
|
1,953
|
1,884
|
1,953
|
1,738
|
Six Months Ended
September 30,
|
||||||||
|
2013
|
2012
|
||||||
Cash flows from operating activities:
|
|
|
||||||
Net loss
|
$
|
(1,360
|
)
|
$
|
(1,963
|
)
|
||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
Stock compensation expense
|
175
|
312
|
||||||
Fair value adjustment of common stock warrants
|
(10
|
)
|
(3
|
)
|
||||
Depreciation
|
15
|
1
|
||||||
Loss on disposal of property and equipment
|
--
|
17
|
||||||
Amortization of intangible assets
|
105
|
20
|
||||||
Accrued interest note receivable
|
(17
|
)
|
(17
|
)
|
||||
Accrued interest promissory note
|
3
|
--
|
||||||
Deferred tax liability
|
--
|
(336
|
)
|
|||||
Tax benefit related to intangibles
|
(41
|
)
|
--
|
|||||
|
||||||||
Changes in operating assets and liabilities:
|
||||||||
Prepaid expenses and other assets
|
(8
|
)
|
(57
|
)
|
||||
Accounts payable, accrued expenses and other liabilities
|
40
|
2
|
||||||
Current assets and liabilities from discontinued operations, net
|
(139
|
)
|
316
|
|||||
Net cash used in operating activities
|
(1,237
|
)
|
(1,708
|
)
|
||||
Cash flows from investing activities:
|
||||||||
Acquisition of property and equipment
|
(11
|
)
|
(71
|
)
|
||||
Cash received from acquisition
|
--
|
476
|
||||||
Issuance of note receivable
|
--
|
(300
|
)
|
|||||
Net cash provided by (used in) investing activities
|
(11
|
)
|
105
|
|||||
Net decrease in cash and cash equivalents
|
(1,248
|
)
|
(1,603
|
)
|
||||
Cash and cash equivalents at beginning of period
|
4,039
|
7,820
|
||||||
Cash and cash equivalents at end of period
|
$
|
2,791
|
$
|
6,217
|
||||
|
||||||||
Supplemental disclosure of non-cash activities:
|
||||||||
Shares issued in CollabRx acquisition
|
$
|
--
|
$
|
932
|
||||
Note Receivable used as consideration for CollabRx acquisition
|
$
|
--
|
$
|
300
|
||||
Promissory Note issued in CollabRx acquisition
|
$
|
--
|
$
|
500
|
||||
Fair value of assets acquired in CollabRx acquisition
|
$
|
--
|
$
|
2,253
|
||||
Liabilities assumed in CollabRx acquisition
|
$
|
--
|
$
|
997
|
· | Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. |
· | Level 2: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument. |
· | Level 3: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. |
|
Six Months Ended
September 30,
|
|||||||
|
2013
|
2012
|
||||||
Balance at the beginning of the period
|
$
|
10
|
$
|
19
|
||||
Change in fair value recorded in earnings
|
(10
|
)
|
(3
|
)
|
||||
Balance at the end of the period
|
$
|
-
|
$
|
16
|
STOCK OPTIONS:
|
2013
|
2012
|
||||||
Expected life (years)
|
6.0
|
6.0
|
||||||
Volatility
|
152.4
|
%
|
157.5
|
%
|
||||
Risk-free interest rate
|
1.55
|
%
|
0.62
|
%
|
||||
Dividend yield
|
0
|
%
|
0
|
%
|
|
Shares
|
Weighted-
Average
Exercise
Price
|
Weighted-
Average
Remaining
Contractual
Term (in Years)
|
Aggregate
Intrinsic
Value
|
||||||||||||
Beginning outstanding
|
263,876
|
$
|
10.23
|
|
|
|||||||||||
Granted
|
29,499
|
$
|
3.94
|
|
|
|||||||||||
Expired
|
--
|
$
|
-
|
|
|
|||||||||||
|
|
|
||||||||||||||
Ending outstanding
|
293,375
|
$
|
9.60
|
7.34
|
$
|
27,448.00
|
||||||||||
Ending vested and expected to vest
|
293,096
|
$
|
9.59
|
7.34
|
$
|
27,435.00
|
||||||||||
Ending exercisable
|
177,057
|
$
|
13.32
|
6.17
|
$
|
20,648.00
|
Range of
Exercise Prices
|
Number
Outstanding
As of
September 30,
2013
|
Weighted-
Average
Remaining
Contractual
Term
(in years)
|
Weighted-
Average
Exercise
Price
|
Number
Exercisable
As of
September 30,
2013
|
Weighted-
Average
Exercise
Price
As of
September 30,
2013
|
|||||||||||||||||||||
$
|
2.90
|
$
|
6.00
|
193,828
|
8.98
|
$
|
3.83
|
77,579
|
$
|
3.75
|
||||||||||||||||
6.25
|
11.70
|
45,358
|
5.14
|
11.50
|
45,358
|
11.50
|
||||||||||||||||||||
17.80
|
28.10
|
39,244
|
3.97
|
21.63
|
39,244
|
21.63
|
||||||||||||||||||||
34.20
|
61.80
|
13,998
|
1.68
|
43.95
|
13,998
|
43.95
|
||||||||||||||||||||
89.52
|
174.00
|
947
|
0.93
|
93.95
|
878
|
93.95
|
||||||||||||||||||||
$
|
2.90
|
$
|
174.00
|
293,375
|
7.34
|
$
|
9.60
|
177,057
|
$
|
13.32
|
|
Number
of
|
Weighted-
Average
Grant Date
|
||||||
Balance March 31, 2013
|
183,904
|
$
|
2.67
|
|||||
Granted
|
-
|
$
|
-
|
|||||
Forfeited
|
-
|
$
|
-
|
|||||
Vested
|
(34,750
|
)
|
$
|
2.24
|
||||
Balance, September 30, 2013
|
149,154
|
$
|
2.77
|
|
Three Months Ended
September 30,
|
Six Months Ended
September 30,
|
||||||||||||||
|
2013
|
2012
|
2013
|
2012
|
||||||||||||
|
|
|
|
|
||||||||||||
Loss from continuing operations
|
$
|
(836
|
)
|
$
|
(1,281
|
)
|
$
|
(1,515
|
)
|
$
|
(1,959
|
)
|
||||
|
||||||||||||||||
Income (loss) from discontinued operations, net of taxes
|
273
|
(3
|
)
|
155
|
(4
|
)
|
||||||||||
|
||||||||||||||||
Net loss applicable to common stockholders
|
$
|
(563
|
)
|
$
|
(1,284
|
)
|
$
|
(1,360
|
)
|
$
|
(1,963
|
)
|
||||
Basic and diluted:
|
||||||||||||||||
Weighted-average common shares outstanding
|
1,953
|
1,884
|
1,953
|
1,738
|
||||||||||||
Weighted-average common shares used in per share computation
|
1,953
|
1,884
|
1,953
|
1,738
|
||||||||||||
|
||||||||||||||||
Net loss per share from continuing operations:
|
||||||||||||||||
Basic and diluted
|
$
|
(0.43
|
)
|
$
|
(0.68
|
)
|
$
|
(0.78
|
)
|
$
|
(1.13
|
)
|
||||
Net income (loss) per share from discontinued operations:
|
||||||||||||||||
Basic and diluted
|
$
|
0.14
|
$
|
(0.00
|
)
|
$
|
0.08
|
$
|
(0.00
|
)
|
||||||
Net loss per share:
|
||||||||||||||||
Basic and diluted
|
$
|
(0.29
|
)
|
$
|
(0.68
|
)
|
$
|
(0.70
|
)
|
$
|
(1.13
|
)
|
|
September 30,
2013
|
March 31,
2013*
|
|
|||||
|
|
|||||||
Assets of Discontinued Operations:
|
|
|||||||
Accounts and other receivables, net of allowances for sales returns and doubtful accounts of $0
|
$
|
365
|
$
|
4
|
||||
Prepaid expenses and other current assets
|
-
|
7
|
||||||
Total assets of discontinued operations
|
$
|
365
|
$
|
11
|
||||
|
||||||||
Liabilities of Discontinued Operations:
|
||||||||
Accrued expenses and other current liabilities
|
$
|
89
|
$
|
16
|
||||
Total liabilities of discontinued operations
|
$
|
89
|
$
|
16
|
|
Revenue for the
Three Months Ended
September 30,
|
Revenue for the
Six Months Ended
September 30,
|
||||||||||||||
|
2013
|
2012
|
2013
|
2012
|
||||||||||||
Segment Revenue:
|
|
|
|
|
||||||||||||
Genomics based technology information
|
$
|
251
|
$
|
50
|
$
|
521
|
$
|
50
|
||||||||
Solar power management services
|
--
|
25
|
--
|
50
|
||||||||||||
Total revenue
|
$
|
251
|
$
|
75
|
$
|
521
|
$
|
100
|
|
Three Months Ended
September 30,
|
Six Months Ended
September 30,
|
||||||||||||||
|
2013
|
2012
|
2013
|
2012
|
||||||||||||
|
|
|
|
|
||||||||||||
Revenue
|
$
|
251
|
$
|
50
|
$
|
521
|
$
|
50
|
||||||||
Revenue - related party
|
--
|
25
|
--
|
50
|
||||||||||||
Total revenue
|
251
|
75
|
521
|
100
|
||||||||||||
Cost of revenue
|
18
|
20
|
36
|
20
|
||||||||||||
Gross profit
|
233
|
55
|
485
|
80
|
||||||||||||
Operating expenses:
|
||||||||||||||||
Engineering
|
457
|
328
|
671
|
328
|
||||||||||||
Research and development
|
27
|
--
|
157
|
--
|
||||||||||||
Sales and marketing
|
63
|
49
|
122
|
49
|
||||||||||||
General and administrative
|
558
|
970
|
1,117
|
1,682
|
||||||||||||
Total operating expenses
|
1,105
|
1,347
|
2,067
|
2,059
|
||||||||||||
Operating loss
|
(872
|
)
|
(1,292
|
)
|
(1,582
|
)
|
(1,979
|
)
|
||||||||
Other income, net
|
16
|
11
|
26
|
20
|
||||||||||||
Loss before income tax benefit
|
(856
|
)
|
(1,281
|
)
|
(1,556
|
)
|
(1,959
|
)
|
||||||||
Income tax benefit
|
(20
|
)
|
--
|
(41
|
)
|
--
|
||||||||||
Loss from continuing operations
|
(836
|
)
|
(1,281
|
)
|
(1,515
|
)
|
(1,959
|
)
|
||||||||
Income (loss) from discontinued operations, net of taxes
|
273
|
(3
|
)
|
155
|
(4
|
)
|
||||||||||
Net loss
|
$
|
(563
|
)
|
$
|
(1,284
|
)
|
$
|
(1,360
|
)
|
$
|
(1,963
|
)
|
||||
|
||||||||||||||||
Net loss per share from continuing operations:
|
||||||||||||||||
Basic and diluted
|
$
|
(0.43
|
)
|
$
|
(0.68
|
)
|
$
|
(0.78
|
)
|
$
|
(1.13
|
)
|
||||
Net income (loss) per share from discontinued operations:
|
||||||||||||||||
Basic and diluted
|
$
|
0.14
|
$
|
-
|
$
|
0.08
|
$
|
-
|
||||||||
Net loss per share:
|
||||||||||||||||
Basic and diluted
|
$
|
(0.29
|
)
|
$
|
(0.68
|
)
|
$
|
(0.70
|
)
|
$
|
(1.13
|
)
|
||||
|
||||||||||||||||
Weighted-average shares used in per share computation:
|
||||||||||||||||
Basic and diluted
|
1,953
|
1,884
|
1,953
|
1,738
|
Contractual obligations:
|
|
Less than
|
|
|
After
|
|||||||||||||||
|
Total
|
1 Year
|
1-3 Years
|
3-5 Years
|
5 Years
|
|||||||||||||||
Non-cancelable operating lease obligations
|
$
|
493
|
$
|
122
|
$
|
252
|
$
|
119
|
$
|
-
|
||||||||||
Total contractual cash obligations
|
$
|
493
|
$
|
122
|
$
|
252
|
$
|
119
|
$
|
-
|
· | Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. |
· | Level 2: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument. |
· | Level 3: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. |
|
Six Months Ended
September 30,
|
|||||||
|
2013
|
2012
|
||||||
Balance at the beginning of the period
|
$
|
10
|
$
|
19
|
||||
Change in fair value recorded in earnings
|
(10
|
)
|
(3
|
)
|
||||
Balance at the end of the period
|
$
|
-
|
$
|
16
|
·
|
operating results of CollabRx;
|
·
|
operating results of any companies that we may acquire in the future;
|
·
|
fluctuations in demand for our products, and the timing of agreements with strategic partners in the health care marketplace;
|
·
|
the timing of new products and product enhancements;
|
·
|
changes in the growth rate of the health care marketplace;
|
·
|
our ability to control costs, including operations expenses;
|
·
|
our ability to develop, induce and gain market acceptance for new products and product enhancements;
|
·
|
changes in the competitive environment, including the entry of new competitors and related discounting of products;
|
·
|
adverse changes in the level of economic activity in the United States or other major economies in which we do business;
|
·
|
renewal rates and our ability to up-sell additional products;
|
·
|
the timing of customer acquisitions;
|
·
|
the timing of revenue recognition for our sales; and
|
·
|
future accounting pronouncements or changes in our accounting policies.
|
·
|
we fail to introduce these new products or enhancements;
|
·
|
we fail to successfully manage the transition to new products from the products they are replacing;
|
·
|
we do not invest our development efforts in appropriate products or enhancements for markets in which we now compete and expect to compete;
|
·
|
we fail to predict the demand for new products following their introduction to market; or
|
·
|
these new products or enhancements do not attain market acceptance.
|
·
|
longer operating histories;
|
·
|
the capacity to leverage their sales efforts and marketing expenditures across a broader portfolio of products;
|
·
|
broader distribution and established relationships with partners;
|
·
|
access to larger customer bases;
|
·
|
greater customer support;
|
·
|
greater resources to make acquisitions;
|
·
|
larger intellectual property portfolios; and
|
·
|
the ability to bundle competitive offerings with other products and services.
|
· | difficulties in identifying and acquiring complementary products, technologies or businesses; |
· | substantial cash expenditures; |
· | incurrence of debt and contingent liabilities, some of which we may not identify at the time of acquisition; |
· | difficulties in assimilating the operations and personnel of the acquired companies; |
· | diversion of management’s attention away from other business concerns; |
· | risk associated with entering markets in which we have limited or no direct experience; |
· | potential loss of key employees, customers and strategic alliances from either our current business or the target company’s business; and |
· | delays in customer purchases due to uncertainty and the inability to maintain relationships with customers of the acquired businesses. |
· | not experimental or investigational; |
· | medically necessary; |
· | appropriate for the specific patient; |
· | cost-effective; |
· | supported by peer-reviewed publications; |
· | included in clinical practice guidelines; and |
· | supported by clinical utility studies. |
· | our quarterly or annual earnings or those of other companies in our industry; |
· | announcements by us or our competitors of significant contracts or acquisitions; |
· | changes in accounting standards, policies, guidance, interpretations or principles; |
· | general economic and stock market conditions, including disruptions in the world credit and equity markets; |
· | the failure of securities analysts to cover our common stock; |
· | future sales of our common stock; and |
· | the other factors described in these “Risk Factors.” |
Exhibit
Number
|
Description
|
Certificate of Incorporation, as amended.
|
|
Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
Certification of the Acting Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
Certification of the Chief Executive Officer and Acting Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
COLLABRX, INC.
|
(Registrant) | |
|
|
|
/s/ THOMAS R. MIKA
|
Thomas R. Mika
|
|
Date: November 14, 2013
|
Acting Chief Financial Officer
|
|
STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 09:05 API 09/20/1995
950218616 - 2545851
|
Tegal Corporation Limited
|
|
||
By: |
/s/ David Curtis
|
|
|
|
David Curtis
|
|
|
STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 09:05 API 09/20/1995
950218616 - 2545851
|
(a) | In the event of any liquidation, dissolution or winding up of this Corporation, whether voluntary or not, the holders of the Series C Preferred Stock shall be entitled to receive an amount per share equal to the Series C Issue Price (as such price may be adjusted for stock splits, combinations or similar events with respect to such series of Preferred Stock) plus all declared and unpaid dividends, if any, before any amount shall be paid to the holders of the Series D Preferred Stock, Series A Preferred Stock and Common Stock. If, upon the occurrence of a liquidation, dissolution or winding up, the assets and surplus funds distributed among the holders of the Series C Preferred Stock shall be insufficient to permit the payment to such holders of the full preferential amount then the entire assets and surplus funds legally available for distribution shall be distributed ratably among the holders of the Series C Preferred Stock. |
(b) | In the event of any liquidation, dissolution or winding up of this Corporation, whether voluntary or not, the holders of the Series D Preferred Stock shall be entitled to receive an amount per share equal to the Series D Issue Price (as such price may be adjusted for stock splits, combinations or similar events with respect to such series of Preferred Stock) plus all declared and unpaid dividends, if any, and the holders of the Series A Preferred Stock shall be entitled to receive an amount per share equal to the Series A Issue Price (as such price may be adjusted for stock splits, combinations or similar events with respect to such series of Preferred Stock) plus all declared and unpaid dividends, if any, before any amount shall be paid to the holders of the Common Stock. If, upon the occurrence of a liquidation, dissolution or winding up, the assets and surplus funds distributed among the holders of the Series D Preferred Stock and Series A Preferred Stock shall be insufficient to permit the payment to such holders of the full preferential amount then the entire assets and surplus funds legally available for distribution shall be distributed ratably among the holders of the Series D Preferred Stock and Series A Preferred Stock such that the ratio of the assets and surplus funds being distributed to holders of Series A Preferred Stock, on a per share basis, to the assets and surplus funds being distributed to holder of Series D Preferred Stock, on a per share basis, is the same as the ratio of the Series A Issue Price (as such price may be adjusted for stock splits, combinations or similar events with respect to such series of Preferred Stock) plus all declared and unpaid dividends, if any, to the Series D Issue Price (as such price may be adjusted for stock splits, combinations or similar events with respect to such series of Preferred Stock) plus all declared and unpaid dividends, if any. |
(c) | If, upon the occurrence of a liquidation, dissolution or winding up, after the payment to the holders of Series C Preferred Stock, Series D Preferred Stock and Series A Preferred Stock of the preferential amount, assets or surplus funds remain in this Corporation, the holders of Series C Preferred Stock, Series D Preferred Stock, Series A Preferred Stock and the holders of Common Stock shall be entitled to share in all such remaining assets and surplus funds in the same manner as if all shares of Series C Preferred Stock, Series D Preferred Stock and Series A Preferred Stock had been converted into Common Stock. |
(d) | For the purposes of this Article, a liquidation, dissolution or winding up of the Corporation shall be deemed to be occasioned by, and to include, the sale by the Corporation of substantially all of its assets or the acquisition of the Corporation by another entity by means of merger or consolidation resulting in the exchange of the outstanding shares of the Corporation for securities or consideration issued, or caused to be issued, by the acquiring company or its subsidiary. |
(a)
|
Subject to Section (E)(xiv) with respect to the Series A Preferred Stock, Series C Preferred Stock and Series D Preferred Stock, in case the Corporation shall at any time after the Issuance Date with respect to the Series A Preferred Stock issue or sell any Common Stock without consideration, or for a consideration per share less than the applicable Current Conversion Price for the Series A Preferred Stock, Series C Preferred Stock and Series D Preferred Stock, the, and thereafter successively upon each such issuance or sale, the applicable Current Conversion Price for such Series A Preferred Stock, Series C Preferred Stock and Series D Preferred Stock shall simultaneously with such issuance or sale be adjusted to a Conversion Price (calculated to the nearest cent) determined by dividing (A) an amount equal to (i) the total number of shares of Common Stock Outstanding when the applicable Current Conversion Price became effective multiplied by the applicable Current Conversion Price, plus (ii) the aggregate of the amount of all consideration, if any, received by the Corporation for the issuance or sale of Common Stock since the applicable Current Conversion Price became effective, by (B) the total number of shares of Common Stock Outstanding immediately after such issuance or sale; provided, however, that the applicable Conversion Price shall at no time exceed US $5.25 for the Series C Preferred Stock and Series D Preferred Stock and US $2.4304 for the Series A Preferred Stock (as adjusted for stock splits, combinations and similar events). For the purposes of this provision the following shall apply:
|
(1) | In the case of the issuance or sale of additional Common Stock for cash, the consideration received by the Corporation therefor shall be deemed to be the amount of cash received by the Corporation for such shares (or, if such shares are offered by the Corporation for subscription, the subscription price, or, if such shares are sold to underwriters or dealers for public offering without a subscription offering, the initial public offering price), without deducting therefrom any compensation or discount paid or allowed to underwriters or dealers or others performing similar services or for any expenses incurred in connection therewith. |
(2) | In case of the issuance (otherwise than upon conversion or exchange of Convertible Securities) or sale of additional Common Stock, Options or Convertible Securities for a consideration other than cash or a consideration a part of which shall be other than cash, the fair value of such consideration as determined by the Board of Directors of the Corporation in the good faith exercise of its business judgment, irrespective of the accounting treatment thereof, shall be deemed to be the value, for purposes of this Paragraph (E), of the consideration other than cash received by the Corporation for such securities. |
(3)
|
In case the Corporation shall in any manner issue or grant any options or any Convertible Securities, the total maximum number of shares of Common Stock issuable upon the exercise of such Options or upon conversion or exchange of the total maximum amount of such Convertible Securities at the time such Convertible Securities first became convertible or exchangeable shall (as of the date of issue or grant of such Options or, in the case of the issue or sale of Convertible Securities other than where the same are issuable upon the exercise of Options, as of the date of such issue or sale be deemed to be issued and to be outstanding for the purpose of this Section (E)(iv) and to have been issued for the sum of the amount (if any) paid for such Options or Convertible Securities and the minimum amount (if any) payable upon the exercise of such Options or upon conversion or exchange of such Convertible Securities at the time such Convertible Securities first become convertible or exchangeable; provided that, subject to the provisions of Section (E)(v) no further adjustments of the applicable Conversion Price shall be made upon the actual issuance of any such Common Stock or Convertible Securities or upon the conversion or exchange of any such Convertible Securities.
|
(i)
|
amend or repeal any provision of, or add any provision to, the Corporation's Bylaws or Certificate of Incorporation;
|
(ii) | authorize or issue shares of any class or series of stock not authorized herein having any preference or priority as to dividends, redemptions or distribution of assets superior to or on a parity with any such preference or priority of the Series A Preferred Stock, Series C Preferred Stock or Series D Preferred Stock or which in any manner adversely affects the rights of the holders of shares of Series A Preferred Stock, Series C Preferred Stock or Series D Preferred Stock; authorize or issue shares of stock of any class or series or any bonds, debentures, notes or other obligations convertible into or exchangeable for, or having options rights to purchase, any shares of stock of this Corporation having any preference or priority as to dividends or assets superior to or on a parity with any such preference or priority of the Series A Preferred Stock, Series C Preferred Stock or Series D Preferred Stock; or authorize or issue shares of stock of any class or series having voting rights other than voting rights required by law; |
(iii) | reclassify any class or series of any Common Stock into shares having any preference or priority as to dividends or assets superior to or on a parity with any such preference or priority of Series A Preferred Stock, Series C Preferred Stock or Series D Preferred Stock. |
(iv) | except as provided in Sections (C)(vi) or (C)(ix) apply any of its assets to the redemption, retirement, purchase or acquisition, directly or indirectly, through subsidiaries or otherwise,of any shares of any class of Common Stock, except from employees, advisors, officers, directors and consultants of, and persons performing services for the Corporation or its subsidiaries on terms approved by the board of directors upon termination of employment or association; |
(v)
|
(a) sell, lease, convey or otherwise dispose of or transfer all or a substantial portion of its assets, property or business, or (b) merge into or consolidate with any other company (other than a wholly owned subsidiary of the Corporation);
|
(vi) | pay any dividend on the outstanding shares of Common Stock; or |
(vii)
|
dissolve, liquidate or wind up the affairs of the Corporation.
|
NAME
|
MAILING ADDRESS
|
David Curtis
|
2201 South McDowell Boulevard
|
|
Petaluma, California 94953-6020
|
|
/s/ David Curtis
|
|
|
David Curtis, Incorporator
|
|
|
STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 03:30 PH 10/16/1995
950237895 - 2545851
|
1.
|
Each seven (7) shares of the Corporation's Common Stock, par value $0.01 per share, issued and outstanding or held in treasury immediately prior to the Effective Time shall, automatically and without any action on the part of the respective holders thereof, be reclassified into one (1) share of Common Stock, par value $0.01 per share, of the Corporation and each stock certificate that, immediately prior to the Effective Time, represented seven (7) shares of the Corporation's Common Stock, par value $0.01 per share, shall, from and after the Effective Time, represent one (1) share of Common Stock, par value $0.01 per share.
|
|
2. | Each seven (7) shares of the Corporation's Series A Preferred Stock, par value $0.01 per share, issued and outstanding or held in treasury immediately prior to the Effective Time shall, automatically and without any action or the part of the respective holders thereof, be reclassified into one (1) share of Series A Preferred Stock, par value $0.01 per share, of the Corporation and each stock certificate that, immediately prior to the Effective Time, represented seven (7) shares of the Corporation's Series A Preferred Stock, par value $0.01 per share, shall, from and after the Effective Time, represent one (1) share of Series A Preferred Stock, par value $0.01 per share. |
3. | Each seven (7) shares of the Corporation's Series C Preferred Stock, par value $0.01 per share, issued and outstanding or held in treasury immediately prior to the Effective Time shall, automatically and without any action on the part of the respective holders thereof, be reclassified into one (1) share of Series C Preferred Stock, par value $0.01 per share, of the Corporation and each stock certificate that, immediately prior to the Effective Time, represented seven (7) shares of the Corporation's Series C Preferred Stock, par value $0.01 per share, shall, from and after the Effective Time, represent one (1) share of Series C Preferred Stock, par value $0.01 per share, |
4. | Each seven (7) shares of the Corporation's Series D Preferred Stock, par value $0.01 per share, issued and outstanding or held in treasury immediately prior to the Effective Time shall, automatically and without any action on the part of the respective holders thereof, be reclassified into one (1) share of Series D Preferred Stock, par value $0.01 per share, of the Corporation and each stock certificate that, immediately prior to the Effective Time, represented seven (7) shares of the Corporation's Series D Preferred Stock, par value $0.01 per share, shall, from and after the Effective Time, represent one (1) share of Series D Preferred Stock, par value $0.01 per share. |
5.
|
Notwithstanding the foregoing, to the extent that a stockholder of the Corporation would receive fractional shares of the Corporation
1
s stock pursuant to sub-paragraphs (1), (2), (3) and (4) hereof, such members shall instead receive a cash payment from the Corporation in an amount equal to the product of $10.00 multiplied by, in the case of fractional shares of Common Stock, such fractional amount, and in the case of shares of Preferred Stock, by the amount of fractional shares of Common Stock to which such stockholder would have been entitled had the fractional shares of Preferred Stock been converted to Common Stock prior to the proposed reverse stock split,"
|
|
TEGAL CORPORATION
|
|
|
|
By:
|
/s/ David Curtis
|
|
|
Name:
|
David Curtis
|
|
|
Title:
|
Vice President, Secretary, Treasurer
|
|
|
STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 09:00 AM 10/25/1995
950247338 - 2545851
|
|
/s/ David Curtis
|
|
|
David Curtis, Secretary
|
|
|
STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 09:00 AH 12/21/1995 9
50303514 - 2545851
|
|
TEGAL CORPORATION, a Delaware corporation
|
|
|
|
|
|
|
|
By:
|
/s/ Robert V; Hery
|
|
|
Name:
|
Robert V; Hery
|
|
|
Title:
|
President
|
|
|
State of Delaware
Secretary of State
Division of Corporations
Delivered 01:45 PM 09/09/2003
FILED 01:45 PM 09/09/2003
SRV 030580279 - 2545851 FILE
|
|
/s/ Michael L. Parodi
|
|
|
Michael L. Parodi
|
|
|
President and Chief Executive Officer
|
|
|
State
of Delaware
Secretary of State
Division of Corporations
Delivered 03:31 PM 09/13/2005
FILED 03:31 PM 09/13/2005
SRV 050749064 - 2545851 FILE
|
|
/s/ Thomas R. Mika
|
|
|
Thomas R. Mika
|
|
|
President and Chief Executive Officer
|
|
|
State of Delaware
Secretary of State
Division of Corporations
Delivered 03:54 PM 07/21/2006
FILED 03:54 PM 07/21/2006
SRV 060691733 - 2545851 FILE
|
|
/s/ Thomas R.
Mika
|
|
|
Thomas R. Mika
|
|
|
President & Chief Executive Officer
|
|
|
State of Delaware
Secretary of State
Division of Corporations
Delivered 10:42 AM 09/25/2007
FILED 10:40 AM 09/25/2007
SRV 071048376 - 2545851
|
|
/s/ Thomas R. Mika
|
|
|
Thomas R. Mika
|
|
|
President & Chief Executive Officer
|
|
|
/s/ Christine T. Hergenrother
|
|
|
Christine T. Hergenrother Secretary
|
|
2545851 8100
|
|
|
|
/s/ Jeffrey W. Bullock
|
|
110413194
online at corp.delaware.gov/authver.shtml
|
Jeffrey W. Bullock, Secretary of State
DATE: 04-14-11
AUTHENTICATION: 8693015
|
|
State of Delaware
Secretary of State
Division of Corporations
Delivered 05:48 PM 04/13/2011
FILED 05:19 PM 04/13/2011
SRV 110413194 - 2545851 FILE
|
|
TEGAL CORPORATION
|
|
|
|
|
|
|
|
By:
|
/s/ Thomas R. Mika
|
|
|
Name:
|
Thomas R. Mika
|
|
|
Title:
|
President and Chief Executive Officer
|
|
|
||
2545851 8100
|
/s/ Jeffrey W. Bullock
|
|
110726225
You may verify this certificate
online at corp.delaware.gov/authver.shtml
|
Jeffrey W. Bullock, Secretary of State
AUTHENTICATION: 8836166
DATE: 06-15-11
|
State of Delaware
Secretary of State
Division of Corporations
Delivered 03:31PM 06/15/2011
FILED 03:29 PM 06/15/2011
SRV 110726225 - 2545851 FILE
|
|
/s/ Thomas R. Mika | ||
|
Thomas
R. Mika
|
|
|
Chairman, President & CEO
|
|
||
2545851 8100
|
/s/ Jeffrey W. Bullock
|
|
121066539
You may verify this certificate
online
at corp.delaware.gov/authver.shtml
|
Jeffrey W. Bullock, Secretary of State
AUTHENTICATION: 9871285
DATE: 09-25-12
|
State of Delaware
Secretary of State
Division of Corporations
Delivered 03:32 PM 09/25/2012
FILED 03:28 PM 09/25/2012 S
RV 121066539 - 2545851 FILE
|
|
|
TEGAL CORPORATION
|
|
|
|
|
|
|
|
By:
|
/s/ Thomas R. Mika
|
|
|
Name:
|
Thomas R. Mika
|
|
|
Title:
|
President and Co-Chief Executive Officer
|
|
1. | I have reviewed this quarterly report on Form 10-Q of CollabRx, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer(s), if any, and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
5. | The registrant’s other certifying officer(s), if any, and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting. |
Date: November 14, 2013
|
/s/ Thomas R. Mika
|
|
President and Chief Executive Officer
|
1. | I have reviewed this quarterly report on Form 10-Q of CollabRx, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer(s), if any, and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
5. | The registrant’s other certifying officer(s), if any, and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting. |
Date: November 14, 2013
|
/s/ Thomas R. Mika
|
|
Acting Chief Financial Officer
|
/s/ Thomas R. Mika
|
|
President and Chief Executive Officer
|
|
November 14, 2013
|
|
/s/ Thomas R. Mika
|
|
Acting Chief Financial Officer
|
|
November 14, 2013
|
|